扶正化瘀片联合西药治疗慢性肝炎肝硬化的临床疗效

Clinical Analysis of Fuzheng Huayu Tablet Combined with Western Medicine in Treating Chronic Hepatitis Cirrhosis

目的:探究扶正化瘀片联合西药治疗慢性肝炎肝硬化的临床效果。方法:将2014年6月—2017年6月期间的156例慢性肝炎肝硬化患者随机分成两组,对照组采用替卡韦片治疗,观察组采用扶正化瘀片联合恩替卡韦治疗,比较两组患者血清血清天冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)水平,肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)水平以及HBV-DNA载量。结果:治疗后,观察组患者血清血清AST、ALT水平,炎症介质TNF-α、IL-6和IL-8水平以及HBV-DNA载量均明显的低于对照组,HBV-DNA转阴率明显高于对照组,比较差异具有显著性(P<0.05)。结论:扶正化瘀片联合恩替卡韦降低了肝脏炎症,提高了HBV-DNA转阴率,有效的改善了肝功能。

Objective： To explore the clinical effect of Fuzheng Huayu Tablet combined with western medicine in the treatment of chronic hepatitis cirrhosis. Methods： A total of 156 patients with chronic hepatitis cirrhosis were randomly divided into two groups from June 2014 to June 2017. The control group was treated with ticaravir tablets while the observation group was treated with Fuzheng Huayu Tablet combined with entecavir. To compare the levels of serum aspartate aminotransferase（ AST）,alanine aminotransferase（ ALT）,tumor necrosis factor-α（ TNF-α）,interleukin-6（ IL-6） and interleukin-6（ IL-6） Interleukin-8（ IL-8） and HBV-DNA loading. Results： After treatment,serum AST,ALT levels,inflammatory mediators TNF-α,IL-6and IL-8 levels and HBV-DNA loading were significantly lower in the observation group than those in the control group. The HBV-DNA negative rate was significantly higher than that in the control group and the difference was significant（ P〈0. 05）. Conclusion： Fuzheng Huayu Tablet combined with entecavir reduced liver inflammation,increased HBV-DNA negative rate and effectively improved the liver function.